MDGL Live signals | Maximize Profits with Getagraph.com

BUY 2004 min ago

@ $210.10

Issued: 23 Apr 2024 @ 09:32

Return: -2.59%

Previous signal: Apr 22 - 13:16

Previous signal: Sell

Return: 0.31 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	575 000
Average Volume	584 261
Market Cap	4.30B
EPS	$-5.68 ( 2024-02-29 )
Next earnings date	( $-6.06 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.24
ATR14	$15.23 (7.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Taub Rebecca	Buy	2 676	Common Stock
2024-04-08	Taub Rebecca	Sell	224	Common Stock
2024-04-08	Taub Rebecca	Sell	945	Common Stock
2024-04-08	Taub Rebecca	Sell	300	Common Stock
2024-04-08	Taub Rebecca	Sell	600	Common Stock

INSIDER POWER
-31.13
Last 100 transactions
Buy: 220 053 \| Sell: 418 887

Volume Correlation

Long: -0.85 (strong negative)

Short: -0.91 (very strong negative)

Signal:(37) Neutral

Madrigal Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Madrigal Pharmaceuticals Correlation - Currency/Commodity

-0.78
( moderate negative )

-0.73
( moderate negative )

-0.23
( neutral )

-0.37
( neutral )

-0.66
( moderate negative )

0.78
( moderate )

Madrigal Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-527 000 (0.00 %)
EPS:	$-19.99

Q4	2023
Revenue:	$0
Gross Profit:	$-142 000 (0.00 %)
EPS:	$-5.68

Q3	2023
Revenue:	$0
Gross Profit:	$-135 000 (0.00 %)
EPS:	$-5.34

Q2	2023
Revenue:	$0
Gross Profit:	$-126 000 (0.00 %)
EPS:	$-4.69

Financial Reports:

No articles found.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.